Black Rock Inc. Coherus Bio Sciences, Inc. Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
A detailed history of Black Rock Inc. transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 11,752,500 shares of CHRS stock, worth $18.5 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,752,500
Previous 11,230,522
4.65%
Holding current value
$18.5 Million
Previous $26.8 Million
24.25%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding CHRS
# of Institutions
135Shares Held
77.9MCall Options Held
40.7KPut Options Held
50.1K-
Vanguard Group Inc Valley Forge, PA11.3MShares$17.8 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY10.4MShares$16.3 Million0.3% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY3.04MShares$4.77 Million0.18% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.86MShares$4.49 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.57MShares$4.03 Million0.0% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $122M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...